Addex Therapeutics

We are proud to announce that Indivior has selected clinical candidates from our #GABAB positive #allostericmodulator (PAM) research collaboration. Indivior is developing its candidate in substance use disorder and is responsible all future development. As part of the agreement, Addex Therapeutics has selected a compound to advance independently for the treatment of chronic #cough. #drugdiscovery #pharmapartnering https://lnkd.in/eQ3WfBgc

Data from studies in models of chronic #cough, which will be presented at the Thirteenth London International Cough Symposium (13th LICS) on July 19, showed that our #GABAB positive #allostericmodulator exhibited robust antitussive efficacy, combined with reduced centrally-mediated side-effects and improved tolerability in comparison to #baclofen. We believe that such a compound has the potential to become a best-in-class treatment for chronic cough. https://lnkd.in/eveNWaAf

Our Head of Translational Science, Dr. Mikhail Kalinichev, will present data on our GABAB positive #allostericmodulator #chroniccough program at the Thirteenth London International Cough Symposium taking place July 18 - 19, 2024 at Imperial College in London, U.K. His presentation is scheduled for 12:00 CEST / 11:00 BST, on Friday July 19, 2024 in the Huxley Building. https://lnkd.in/en7naFDn

Today we announced our Q1 2024 financial results. Our CEO, Tim Dyer, and Head of Translational Science, Mikhail Kalinichev, will host a conference call later today at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) to provide an update on business progress and a review of the Addex pipeline. #allostericmodulators #drugdevelopment #financialresults https://lnkd.in/dsNymquj

Our Q1 2024 financial results will be released on June 6, 2024. Join our CEO, Tim Dyer, and Head of Translational Science, Mikhail Kalinichev, as they host a conference call the same day at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT), providing a business update and a review of the Addex pipeline. #allostericmodulators #drugdevelopment #financialresults https://lnkd.in/emhyrfMn

Our CEO, Tim Dyer, will be presenting at the Bio€quity Europe 2024 conference next week in San Sebastián, Spain. In his presentation (14:00 – 14:12 CEST on Monday May 13, 2024 in Room 6 + 7), Mr. Dyer will discuss recent developments at Addex. Reach out if you are interested in meeting Mr Dyer at the conference (IR@addexpharma.com) #allostericmodulators #BioEquity2024 #BioEquityEurope https://lnkd.in/e4QqVmrP

Thanks David Wild and In Vivo Citeline Commercial for covering Addex Therapeutics and outlining our journey for the past 22 years advancing the field of #allostericmodulators. Despite the ups and downs of #drugdevelopment, we continue to make progress, with the over-riding aim of helping patients with #neurologicaldisorders. #CNS #drugdiscovery https://lnkd.in/eNnaqnh6

May is stroke awareness month. When stroke occurs, its vital to act F.A.S.T. to minimize lasting damage such as motor paralysis, loss of sensory function, impaired autonomic functions and impaired cognition leading to deficits in communication, attention and memory. There are currently no drugs to support sensorimotor recovery from stroke and current therapies rely on retraining and physiotherapy, with rehabilitation. At Addex Therapeutics, we are testing dipraglurant, a metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) as a potential treatment for post-stroke sensorimotor recovery. Our aim is to begin phase 2 clinical studies in 2024. #strokemonth

Our CEO, Tim Dyer, will present at Swiss Biotech Association Day 2024 next week in Basel. His presentation is scheduled for 13:45 – 14:00 CEST, on April 23, 2024, in the Samarkand room on the third floor. Mr. Dyer will be available for meetings throughout the conference. Contact ir@addexpharma.com if you’re interested in meeting.   #allostericmodulator #SwissBiotechDay #CNS #drugdevelopment https://lnkd.in/e2epnDAT

Looking forward to providing a corporate update on our results conference call later today and to discussing the recent launch of Neurosterix which we launched with a $63 million series A led by Perceptive Advisors.